Dutch Society for Dermatology and Venereology, Utrecht, The Netherlands.
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Acta Derm Venereol. 2024 May 15;104:adv23901. doi: 10.2340/actadv.v104.23901.
Telemedicine, the provision of remote healthcare, has gained prominence, accelerated by the COVID-19 pandemic. It has the potential to replace routine in-person follow-up visits for patients with chronic inflammatory skin conditions. However, it remains unclear whether telemedicine can effectively substitute in-person consultations for this patient group. This systematic review assessed the effectiveness and safety of telemedicine compared with traditional in-person care for chronic inflammatory skin diseases. A comprehensive search in various databases identified 11 articles, including 5 randomized controlled trials (RCTs) and 1 clinical controlled trial (CCT). These studies evaluated telemedicine's impact on patients with psoriasis and atopic dermatitis, with varying methods like video consultations and digital platforms. The findings tentatively suggest that telemedicine does not seem to be inferior compared with in-person care, particularly in terms of condition severity and quality of life for patients with chronic inflammatory skin diseases. However, these results should be interpreted with caution due to the inherent uncertainties in the evidence. There are indications that telemedicine can offer benefits such as cost-effectiveness, time savings, and reduced travel distances, but it is important to recognize these findings as preliminary, necessitating further validation through more extensive research.
远程医疗,即远程提供医疗服务,在 COVID-19 大流行的推动下得到了重视。它有可能替代慢性炎症性皮肤病患者的常规门诊随访。然而,远程医疗是否能有效替代这一患者群体的门诊咨询,目前仍不清楚。本系统评价评估了远程医疗与传统门诊治疗慢性炎症性皮肤病的效果和安全性。在多个数据库中进行全面检索,共确定了 11 篇文章,包括 5 项随机对照试验(RCT)和 1 项临床对照试验(CCT)。这些研究评估了远程医疗对银屑病和特应性皮炎患者的影响,采用了视频咨询和数字平台等不同方法。研究结果初步表明,远程医疗在慢性炎症性皮肤病患者的病情严重程度和生活质量方面似乎并不逊于传统门诊治疗。然而,由于证据中存在固有不确定性,这些结果应谨慎解读。有迹象表明,远程医疗具有成本效益、节省时间和减少旅行距离等优势,但需要认识到这些发现尚属初步,需要通过更广泛的研究进一步验证。